BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 7592913)

  • 1. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor.
    Lerner EC; Qian Y; Hamilton AD; Sebti SM
    J Biol Chem; 1995 Nov; 270(45):26770-3. PubMed ID: 7592913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes.
    Lerner EC; Qian Y; Blaskovich MA; Fossum RD; Vogt A; Sun J; Cox AD; Der CJ; Hamilton AD; Sebti SM
    J Biol Chem; 1995 Nov; 270(45):26802-6. PubMed ID: 7592920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine.
    Sun J; Blaskovich MA; Knowles D; Qian Y; Ohkanda J; Bailey RD; Hamilton AD; Sebti SM
    Cancer Res; 1999 Oct; 59(19):4919-26. PubMed ID: 10519405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors.
    Fiordalisi JJ; Johnson RL; Weinbaum CA; Sakabe K; Chen Z; Casey PJ; Cox AD
    J Biol Chem; 2003 Oct; 278(43):41718-27. PubMed ID: 12882980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A non-peptide mimetic of Ras-CAAX: selective inhibition of farnesyltransferase and Ras processing.
    Vogt A; Qian Y; Blaskovich MA; Fossum RD; Hamilton AD; Sebti SM
    J Biol Chem; 1995 Jan; 270(2):660-4. PubMed ID: 7822292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
    Morgan MA; Sebil T; Aydilek E; Peest D; Ganser A; Reuter CW
    Br J Haematol; 2005 Sep; 130(6):912-25. PubMed ID: 16156861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I.
    Zhang FL; Kirschmeier P; Carr D; James L; Bond RW; Wang L; Patton R; Windsor WT; Syto R; Zhang R; Bishop WR
    J Biol Chem; 1997 Apr; 272(15):10232-9. PubMed ID: 9092572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAAX peptidomimetic FTI-244 decreases platelet-derived growth factor receptor tyrosine phosphorylation levels and inhibits stimulation of phosphatidylinositol 3-kinase but not mitogen-activated protein kinase.
    McGuire TF; Qian Y; Blaskovich MA; Fossum RD; Sun J; Marlowe T; Corey SJ; Wathen SP; Vogt A; Hamilton AD
    Biochem Biophys Res Commun; 1995 Sep; 214(1):295-303. PubMed ID: 7669049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of protein geranylgeranylation causes a superinduction of nitric-oxide synthase-2 by interleukin-1beta in vascular smooth muscle cells.
    Finder JD; Litz JL; Blaskovich MA; McGuire TF; Qian Y; Hamilton AD; Davies P; Sebti SM
    J Biol Chem; 1997 May; 272(21):13484-8. PubMed ID: 9153192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-298 disrupts MAP kinase activation and G(1)-S transition in Ki-Ras-overexpressing transformed adrenocortical cells.
    Mazet JL; Padieu M; Osman H; Maume G; Mailliet P; Dereu N; Hamilton AD; Lavelle F; Sebti SM; Maume BF
    FEBS Lett; 1999 Oct; 460(2):235-40. PubMed ID: 10544242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion.
    Sun J; Qian Y; Hamilton AD; Sebti SM
    Cancer Res; 1995 Oct; 55(19):4243-7. PubMed ID: 7671229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation.
    McGuire TF; Qian Y; Vogt A; Hamilton AD; Sebti SM
    J Biol Chem; 1996 Nov; 271(44):27402-7. PubMed ID: 8910319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice.
    Sun J; Ohkanda J; Coppola D; Yin H; Kothare M; Busciglio B; Hamilton AD; Sebti SM
    Cancer Res; 2003 Dec; 63(24):8922-9. PubMed ID: 14695209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective inhibition of cancer cell invasion by a geranylgeranyltransferase-I inhibitor.
    Kusama T; Mukai M; Tatsuta M; Matsumoto Y; Nakamura H; Inoue M
    Clin Exp Metastasis; 2003; 20(6):561-7. PubMed ID: 14598891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts.
    Vogt A; Qian Y; McGuire TF; Hamilton AD; Sebti SM
    Oncogene; 1996 Nov; 13(9):1991-9. PubMed ID: 8934546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel protein geranylgeranyltransferase-I inhibitor with high potency, selectivity, and cellular activity.
    Peterson YK; Kelly P; Weinbaum CA; Casey PJ
    J Biol Chem; 2006 May; 281(18):12445-50. PubMed ID: 16517596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro.
    James GL; Goldstein JL; Brown MS
    J Biol Chem; 1995 Mar; 270(11):6221-6. PubMed ID: 7890759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.